Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CDXC - ChromaDex Corp.

IEX Last Trade
5.485
0.010   0.182%

Share volume: 2,824
Last Updated: Fri 27 Dec 2024 08:30:16 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.90%

PREVIOUS CLOSE
CHG
CHG%
$5.48
0.01
0.18%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
29%
Profitability 25%
Dept financing 13%
Liquidity 75%
Performance 25%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
5.85%
1 Month
-26.57%
3 Months
47.63%
6 Months
111.70%
1 Year
286.90%
2 Year
281.63%
Key data
Stock price
$5.48
P/E Ratio 
0.00
DAY RANGE
$5.44 - $5.62
EPS 
$0.00
52 WEEK RANGE
$1.40 - $7.97
52 WEEK CHANGE
$292.31
MARKET CAP 
261.969 M
YIELD 
N/A
SHARES OUTSTANDING 
75.933 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
0.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$657,192
AVERAGE 30 VOLUME 
$656,996
Company detail
CEO: Robert N. Fried
Region: US
Website: chromadex.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. It researches on nicotinamide adenine dinucleotide (NAD+) and develops and commercializes proprietary-based ingredient technologies. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform.

Recent news